CURRICULUM VITAE

Name: Margaret A. Tucker, M.D.

Work Address: Genetic Epidemiology Branch, DCEG, NCI
6120 Executive Boulevard, EPS 7122
Rockville, Maryland 20892-7236

Place of Birth: Newport News, Virginia

Citizenship: United States

Education:

1972 - B.A., Wellesley College
1976 - M.D., Harvard Medical School

Board Certification:

1977 Diplomate, National Board of Medical Examiners.
1977 Licensed physician, state of California.
1982 Diplomate, American Board of Internal Medicine.
1983 Diplomate, American Board of Internal Medicine, Subspecialty of Medical Oncology.
1988 Licensed physician, state of Maryland.

Brief Chronology of Employment:

1975-1976 US Public Health Service COSTEP Program, Epidemiology Branch, National Cancer Institute, under Dr. Joseph F. Fraumeni, Jr.
1976-1977 Intern, Department of Internal Medicine, Stanford University Medical Center, Stanford, California.
1977-1978 Resident, Department of Internal Medicine, Stanford University Medical Center, Stanford, California.
1978-1979 Staff Associate, Environmental Epidemiology Branch, National Cancer Institute.
1979-1981 Clinical Investigator, Environmental Epidemiology Branch, National Cancer Institute.
1981-1983 Fellow, Division of Oncology, Department of Internal Medicine, Stanford University Medical Center, Stanford, California.
1983-1985 Clinical Investigator, Environmental Epidemiology Branch, National Cancer Institute.
1984-2004 Attending Physician, National Naval Medical Center, Medical Oncology.
1985-1987 Coordinator of Family Studies, Environmental Epidemiology Branch, National Cancer Institute.
1987-1992 Head, Family Studies Section, Environmental Epidemiology Branch,

National Cancer Institute.

1987-Date Senior Authorizing Physician, Epidemiology Program, NCI.
1992-Date Chief, Genetic Epidemiology Branch, National Cancer Institute.
2005-Date Director, Human Genetics Program, DCEG, National Cancer Institute.

Professional Affiliations:

American Association of Cancer Research
American Society of Clinical Oncology
American Society of Preventive Oncology
American College of Physicians
American Epidemiological Society

Honors:

1972 Phi Beta Kappa, Wellesley College
1972 Sigma Xi, Wellesley College
1972 Mary White Peterson Prize in Biology, Wellesley College
1986 US Public Health Service Commendation Medal
1989 Oncology Nursing Society/Adria Excellence in Publication Award in Clinical Practice
1990 US Public Health Service Meritorious Service Medal
1991 US Public Health Service Unit Commendation
1992 US Public Health Service Outstanding Unit Citation
1998 US Public Health Service Distinguished Service Medal
1996 General Motors Visiting Professor, Karolinska Institute, Stockholm, Sweden
1999 First Division of Cancer Epidemiology and Genetics Exemplary Service Award
1999 Inaugural Annual Wallace H. Clark, Jr. Lectureship in Cutaneous Oncology and Melanoma Symposium, University of Pennsylvania
2002 NIH Plain Language Award, Excellent Category
2003 US Public Health Service Citation
2007 NIH Merit Award

Committee Memberships:

1990-1998 Public Health Service representative regarding section 1805 of the Radiation Exposure, Compensation Act, P.L. No. 101-426
1991-1993 American Society of Clinical Oncology Program Committee - AIDS/Epidemiology/Supportive Care
1992-1995 Senior Promotions Review Panel, DCE, NCI
1994-1997 Howard Hughes Medical Institute Research Scholars Advisory Group
1994-Date Medical Review Board, U.S. Public Health Service
1995 NCI Streamlining Committee
1995-1999 Intramural Advisory Board of the NCI; Chair 1997-1999
1995-2000 Division of Cancer Epidemiology and Genetics Promotion and Tenure Panel
1995 American Association of Cancer Research Gertrude Elion Cancer Research

	Award Selection Committee
1995-1996	Division of Cancer Epidemiology and Genetics Search Committee for Human Genetics Program Director
1996-1997	American Society of Clinical Oncology Cancer Prevention and Control Committee
1996-1997	American Society of Clinical Oncology Program Committee - Tumor Biology/Human Genetics
1996-1998	Robert Wood Johnson Minority Medical Faculty Development Program mentor
1996	American Association of Cancer Research Rosenthal Foundation Award Selection Committee
1996-1999	American Society of Clinical Oncology Cancer Communications Committee
1996	American Association of Cancer Research Epidemiology/Prevention Subcommittee of the 1997 Program Committee
1996-2000	NCI Office of Cancer Survivorship Steering Committee
1996-1997	Division of Cancer Epidemiology and Genetics Search Committee for Chief of the Laboratory of Population Genetics
1996-2002	Board of Tutors, Clinical Research Training Program, NIH
1997-1998	NCI Executive Committee (IAB Representative)
1997-2001	NCI Cancer Genetics Working Group
1997-2001	NCI Molecular Epidemiology Coordinating Group
1998-2001	NCI By-Pass Budget Editorial Board
1998-1999	Review Committee for OAM Research Intramural Training Program
1998-1999	Division of Cancer Epidemiology and Genetics Search Committee for Chief of the Clinical Genetics Branch
1998-2008	Surgeon General's Research Officers Group Advisory Committee, USPHS
1998	American Association of Cancer Research American Cancer Society Award Selection Committee
1998-1999	National Cancer Advisory Board Working Group on OMB Circular A-110
1998-2001	Chornobyl Oversight Panel, Division of Cancer Epidemiology and Genetics
1998-1999	NCI Planning Committee for national meeting on confidentiality, data security, and cancer research; subcommittee chair of Genetic Studies.
1998-1999	Co-organizer of Workshop on Phakomatoses Revisited, Bethesda, MD
1999	American Association of Cancer Research Program Committee Epidemiology Subcommittee
2000	American Association for Cancer Research Program Committee Prevention and Survivorship Research Subcommittee, Survivorship Research Section
2000-2001	NCI Intramural Program Working Group Steering Committee
2000-2006	DCEG Genotyping Oversight Committee; Chair 2005
2001-2002	American Association for Cancer Research Research Fellowships Selection Committee
2001-Date	Genetics, Genomics, and Proteomics Faculty Steering Committee Liaison for DCEG (Intramural NCI Faculty)
2001-2004	Co-Chair, Cutaneous Carcinogenesis Working Group (Intramural NCI Faculty)
2001-2002	DDIR representative on NICHD tenure track search committee

2001-2003	American Society of Clinical Oncology Advisory Group on Genetic Testing for Cancer Susceptibility
2001-2008	American Society of Clinical Oncology Patient Communication Subcommittee
2002-Date	Ad Hoc reviewer for Cancer Research UK
2003	NIH Roadmap Clinical Research Workforce Training Workgroup
2004	NCI Sarcoma Working Group for response to NCI Sarcoma PRG
2004-2006	Publications Committee, American Association for Cancer Research
2004-Date	Reviewer for European Union Sixth Framework Programme; Cancer Research UK; Irish Cancer Society; Ulster Cancer Foundation; Scottish Executive Health Department Chief Scientist Office
2005	Sarcoma Review Panel, NCI
2005-Date	Clinical Trials Operations Committee, NCI
2006	NCI representative to Trans-NIH IRP Research Initiative
2006-Date	Clinical Trials Management Systems Steering Committee, NCI
2007-Date	NCI representative to NIH Fragile X Research Coordinating Committee
2007-Date	NCI Strategic Action Plan for Melanoma Research Working Group
2007-Date	Chair, Genotyping Review Committee, DCEG
2007-Date	Clinical Trials Policy Implementation Committee, NCI
2007	Search Committee for Branch Chiefs, EGRP, DCCPS, NCI
2008-Date	Ad hoc reviewer for Wellcome Trust
2007-Date	Steering Committee, Center of Excellence in Integrative Cancer Biology and Genomics, IRP, NCI
2007-Date	Co-Chair, Human Genomics and Genetics Working Group, CEICBG, NCI
2007-Date	Chair, Genotyping Review Committee, DCEG, NCI
2007-Date	Chair, Senior Leadership in Genomics Committee, DCEG, NCI

Editorial Boards:

Editorial Board, Journal of the National Cancer Institute 1989-1994
Editorial Board, PLWC Website American Society of Clinical Oncology 2001-2008
Editorial Board, Annals of Internal Medicine 2004-2008
Editorial Board, Journal of Investigative Dermatology 2007-present

Reviewer for Professional Journals:

American Journal of Epidemiology
American Journal of Medicine
American Journal of Public Health
Annals of Internal Medicine
Archives of Dermatology
British Journal of Cancer
Cancer
Cancer Causes and Control
Cancer Epidemiology, Biomarkers and Prevention

Carcinogenesis
International Journal of Epidemiology
Genes, Chromosomes and Cancer
Journal of the American Academy of Dermatology
Journal of the American Medical Association
Journal of Clinical Oncology
Journal of Investigative Dermatology
Journal of the National Cancer Institute
Lancet
Lancet Oncology
Melanoma Research
New England Journal of Medicine

Resource Responsibilities:

1983-Date	Project officer on numerous research and resource contracts for laboratory, clinical, and epidemiologic research efforts
1987-1996	Co-Project Officer for support services contract for environmental and genetic epidemiologic studies
1996-Date	Project Officer for support services contract for genetic epidemiologic studies

Individuals Mentored:

1993-1995	Erich Horn B Howard Hughes Medical Institute - NIH Research Scholar
1995-1996	Reesa Lewis B Howard Hughes Medical Institute - NIH Research Scholar
1996-1997	Cameron Bird B Howard Hughes Medical Institute - NIH Research Scholar
1997-1999	Jennifer Lee B Howard Hughes Medical Institute - NIH Research Scholar
1992-1996	Stacy Nicholson. M.D.
1994-2001	Michael R. DeBaun, M.D., M.P.H.
1992-1995	Biljana Novakovic, M.D.
1991-2001	Jeff Struewing, M.D., M.P.H.
1993-1998	Lea Harty, Ph.D.
1996-Date	Maria Teresa Landi, M.D., Ph.D.
1992-1996	Albert Lin, M.D., M.P.H.
1995-2000	Judith U. Cope, M.D., M.P.H.
1999-2002	D. Elizabeth MacNeil, M.D.

Presentations: Invited Presentations at National/International Meetings (selected recent)

ARole of Adult UVR Exposure in the Risk of Skin Cancers@ Research Workshop on Risks and Benefits of Exposure to Ultraviolet Radiation and Tanning. Bethesda, MD, September 16-18, 1998.

"Clinical Care of Melanoma Prone Families" Seminario di Dermatologia, Azienda Unita

Sanitaria Locale di Cesena, Ospedale "M. Bufalini," Cesena, Italy, October 13, 1998.

"Second Cancers: Can We Affect Risk" American Society of Clinical Oncology fall Educational Session, Chicago, Illinois, November 13, 1998.

AGenetic Risks in Cancer Survivors@ Office of Cancer Survivorship Workshop, Bethesda, Maryland, March 8-9, 1999.

AOrigins of Melanoma@ Meet-the-Expert Sunrise Session, American Association of Cancer Research Annual Meeting, Philadelphia, Pennsylvania, April 10-14, 1999.

ASecond Malignancies after Childhood Cancer: Host and Treatment Risk@ American Society of Clinical Oncology Annual Meeting Educational Session, Atlanta, Georgia, May 15-18, 1999.

“Bright Spots and Burning Issues: Melanoma Etiology in Retrospect and Prospect@ Inaugural Wallace H. Clark Memorial Lecture, University of Pennsylvania, Philadelphia, Pennsylvania, September 30, 1999.

AUse of Tumor Registries for Genetic Epidemiologic Studies@ and AEpidemiology and Genetics of Melanoma@ NCI All Ireland Cancer Conference, Belfast, Ireland, October 3-6, 1999.

ATrends in Lung Cancer Histology and Smoking@ New Perspectives in Small Cell Lung Cancer, Lausanne, Switzerland, October 27-31, 1999.

AProtecting Patient Privacy/Promoting Public Health@ The Future is Now! Clinical and Ethical Implications of Cancer Genetics. McLaughlin Research Insititute. Big Sky, Montana, February 3-5, 2000.

ADysplastic Nevi as a Biomarker for Melanoma Risk@ Common Frontiers in Cancer Research, United States-Japan Cooperative Cancer Research Program, Bethesda, Maryland, February 22-23, 2000.

ACancer Treatment Related Second Cancers@ Meet the Expert Sunrise Session, American Association for Cancer research, San Francisco, California, April 1-5, 2000.

AEpidemiology of Melanoma@ Melanoma: Basic Biology and Immunological Approaches to Therapy, American Association for Cancer Research, Woodlands, Texas, May 3-7, 2000.

AGenetics and Cancer: Oncogenes in Patient Care@ Genes and Society: Impact of New Technologies on Law, Medicine, and Policy, Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, May 11-12, 2000.

“Major Cancer Susceptibility Genes and Radiation: What do We Know?@ Keynote

Address, American Statistical Association Conference on Radiation and Health, Park City, Utah, June 25-28, 2000.

AUltraviolet Radiation as a Risk Factor for Skin Cancers@ Health and the Environment: Climate Change and the Health Effects of Exposure to Ultraviolet Radiation and Exposures to Higher Temperatures and Air Pollutant Concentrations, 8th U.S.-Japan Workshop on Global Climate Change, Bethesda, Maryland, November 13-15, 2000.

ATrends in Melanoma Incidence and Mortality in the United States@ Techological Innovation in a Changing Medical Marketplace, Institute of Medicine, National Academy of Sciences, Washington, D.C., June 14-15, 2001.

AMelanoma on the Rise: Rates and Risk Factors@ Carcinogenesis and Cancer Prevention:Non-Melanoma and Melanoma Skin Cancer, Chao Family Comprehensive Cancer Center, Newport Beach, California, June 22-24, 2001.

AGenetic Susceptibility and Second Cancer Risks@ International Symposium on Radiation and Homeostasis, Kyoto, Japan, July 13-16, 2001.

AAssessing Risk Related to Cancer Susceptibility Genes: Not as Easy as It Seems@ Sunrise Session, American Association for Cancer Research Annual Meeting, San Francisco, CA, April 6-10, 2002.

AThe Genetics of Melanoma: Update and Implications for Clinical Management@ Third Annual Clinical Cancer Genetics: A Practical Application/Case-Based Approach, Johns Hopkins University School of Medicine, Baltimore, MD, April 19, 2002.

AGenetic Epidemiology of Melanoma@ Melanoma 2003: Turning Scientific Discoveries into Clinical Targets, NCI Clinical Treatment Evaluation Program, Bethesda, MD, May 5-9, 2003.

AHost Factors and Risk of Melanoma@ First International Melanoma Research Congress, Philadelphia, PA, June 21-24, 2003.

ASusceptibility Genes in Melanoma@ New Directions in Cancer: Organ Site Research from the Laboratory to the Clinic. AACR Annual Meeting, Washington, DC, July 11-14, 2003.

ARisk Factors for Cutaneous Malignant Melanoma@ Identification and Management of Risk Factors in Skin Cancer. 3rd Euroskin Conference, Stockholm, Sweden, September 16-19, 2003.

AGenetic Epidemiology of Melanoma@ All Ireland Cancer Conference, Cork, Ireland, October 19-22, 2003.

AGenetic Susceptibility and Risk of Melanoma@ Perspectives in Melanoma VI, Miami,

FL, November 13-14, 2003.

AChallenges and Opportunities in Genetic Epidemiology@ and A Genetic Epidemiology of Melanoma@ Cancer 2004, St. James Hospital, Dublin, Ireland, March 11-12, 2004.

AOverview of Genetic Epidemiology@ The 1st King Hussein Cancer Center-NCI (USA) Conference, 4th Jordan Oncology Society Conference, Amman, Jordan April 15-17, 2004.

"The Epidemiology of Melanoma: a Case-Control Study" XIIth Annual Meeting of the PanAmerican Society for Pigment Cell Research and 6th Annual Chao Family Comprehensive Cancer Center Carcinogenesis and Cancer Prevention Conference: Implication of Pigment Cell Biology for Understanding Human Diseases, Newport Beach, CA, June 24-27, 2004.

AGenetic and Environmental Interactions in Melanoma@ 4th Meeting of the International Dermato-Epidemiology Association and the European Dermato-Epidemiology Network, Venice, Italy, October 10-12, 2004.

ADysplastic Nevi: What to Do (or Not)?@; AMelanoma Genetics: Where Are We?@; AGenes or Environment?YES!: Risk Factors in Melanoma-Prone Families@ Educational Sessions in Cancer Genetics and Cancer Prevention Tracks, 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 13-17, 2005.

ASun Exposure and Melanoma Risk@ IPCC Satellite Meeting on the Photobiology of Melanocytes and Melanoma, 19th International Pigment Cell Conference, Reston, VA, Sept 23, 2005.

AMelanoma: Risk, Recognition, Remediation@ Hematology/Oncology Grand Rounds, AMelanoma Risk Factors@ Dermatology Teaching Conference, Henry Ford Hospital, Detroit, MI, Sept 30, 2005.

AWho is at Risk of Melanoma?@ Keystone Symposium: Advances in the Understanding and Treatment of Melanoma, Santa Fe, NM, Jan 18-23, 2006.

AWho is at Risk of Melanoma?@ Georgetown University School of Medicine Medical Oncology Grand Rounds, March 29, 2006.

AGenetic and Environmental Components of Melanoma Risk Prediction@ Vanderbilt University School of Medicine, Nashville, TN, April 19, 2006.

AGenetic Risk Factors in Second Cancer Risks@ Science Writers Seminar, National Cancer Institute, Bethesda MD, Jan 24, 2007.

AEpidemiology of Pediatric Melanoma@ Pediatric Melanoma Workshop, M.D. Anderson Cancer Center, University of Texas, Houston, TX, February 21-22, 2007.

ADeveloping a Strategic Action Plan for Melanoma Research: Prevention@ Strategic Planning Committee for Melanoma Research, National Cancer Institute, Bethesda, MD, February 28, 2007.

ASun Exposure Measurements in Populations@ Vitamin D and Cancer: Current Dilemmas/Future Needs, National Cancer Institute and Office of Dietary Supplements sponsored meeting, Bethesda, MD, May 7, 2007.

"The Promise of Genome-wide Association Studies" American Association for Cancer Research International Conference Advances in Cancer Research: From the Laboratory to the Clinic, Dead Sea, Jordan, March 16-19, 2008.

"Epidemiology of Pediatric and Young Adult Melanoma" in Educational Session: Melanoma in Children, Adolescents, and Young Adults, American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2, 2008.

"Epidemiology of Multiple Primary Cancers Among Adult Cancer Survivors" American Cancer Society/NCI sponsored Third National Conference on Cancer Survivorship, Atlanta, GA, June18-20, 2008.

"Recent Trends in Melanoma Under Age 40" Eastern Cooperative Oncology Group Melanoma Prevention Group, Ft. Lauderdale, FL, Nov. 14-15, 2008.

Peer Reviewed Publications:

1. Li FP, Tucker MA, Fraumeni JF Jr. Childhood cancer in siblings. J Pediatr 1976;88:419-423.

2. Greene MH, Clark WH, Tucker MA, Elder DE, et al. Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature. Lancet 1980;2:1024.

3. Tobacman JK, Greene MH, Tucker MA, Costa J, Kase R, Fraumeni JF Jr. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian cancer-prone families. Lancet 1982;2:795-798.

4. Tucker MA, Greene MH, Clark WH, Kraemer KH, et al. Dysplastic nevi on the scalp of prepubertal children from melanoma-prone families. J Pediatr 1983;103:65-70.

5. Greene MH, Goldin LR, Clark WH Jr, Lovrien E, Kraemer KH, Tucker MA, Elder DE, Fraser MC, Rowe S. Familial cutaneous malignant melanoma--an autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci USA 1983;80:6071-6075.

6. Chak LY, Sikic BI, Tucker MA, Horns RC Jr, Cox RS. Increased incidence of acute nonlymphocytic leukemia following therapy in patients with small cell carcinoma of the lung. J Clin Oncol 1984;2:385-390.

7. Greene MH, Clark WH Jr, Tucker MA, Elder DE, Kraemer KH, Guerry D, Fraser MC. Managing the dysplastic naevus syndrome. Lancet 1984;1:166-167.

8. Tucker MA, Misfeldt D, Coleman CN, Clark WH Jr, Rosenberg SA. Cutaneous malignant melanoma following Hodgkin's disease. Ann Int Med 1985;102:37-41.

9. Greene MH, Clark WH Jr, Tucker MA, Kraemer KH, Elder DE, Fraser MC. The prospective diagnosis of malignant melanoma in a population at high risk: hereditary melanoma and the dysplastic nevus syndrome. Ann Intern Med 1985;102: 458-465.

10. Greene MH, Clark WH Jr, Tucker MA, Elder DE, Kraemer KH, Guerry D, Witmer WK, Thompson J, Matozzo I, Fraser MC. Clinical recognition of acquired precursors of cutaneous malignant melanoma: a color atlas of the familial dysplastic nevus syndrome. N Engl J Med 1985;312:91-97.

11. Tucker MA, Shields JA, Hartge P, Augsburger J, Hoover RN, Fraumeni JF Jr. Sunlight exposure as risk factor for intraocular melanoma. N Engl J Med 1985;313:789-792.

12. Chakravarti A, Bale SJ, Halloran SL, Tucker MA. Etiological heterogeneity in Hodgkin's disease: HLA linked and unlinked determinants of susceptibility independent of histological concordance. Genet Epidemiol 1986;3:407-415.

13. Fraser MC, Tucker MA. Host-susceptibility factors in cancer etiology. Semin Oncol Nurs 1986;3:170-175.

14. Kraemer KH, Tucker MA, Tarone R, Elder D, Clark WH Jr. Cutaneous melanoma risk in dysplastic nevus syndrome types A and B. N Engl J Med 1986;315:1615-1616.

15. Tucker MA, Meadows AT, Boice JD Jr, Stovall M, Oberlin O, Stone BJ, Birch J, Voute PA, Hoover RN, Fraumeni JF Jr. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 1987;78:459-464.

16. Greene MH, Tucker MA, Clark WH Jr, Kraemer KH, Elder DE, Fraser MC. Hereditary melanoma and the dysplastic nevus syndrome: the risk of cancers other than melanoma. J Am Acad Dermatol 1987;16:792-797.

17. Clark JW, Tucker MA, Greene MH. Clinical and laboratory observations in a lymphoma-prone family. Cancer 1987;60:864-869.

18. Tucker MA, D'Angio GJ, Boice JD, Strong LC, Li FP, Stovall M, Stone BJ, Green D, Lombardi F, Newton W, Hoover RN, Fraumeni JF Jr. Bone sarcoma linked to radiotherapy and chemotherapy in children. N Engl J Med 1987;317:588-593.

19. Tucker MA, Fraumeni JF Jr. Treatment-related cancers following gynecologic malignancy. Cancer 1987;60:2117-2122.

20. Sanford KS, Parshad R, Greene MH, Tarone RE, Tucker MA, Jones GM.

Hypersensitivity to G2 chromatid radiation damage in familial dysplastic nevus syndrome. Lancet 1987;2:1111-1116.

21. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second malignancies following Hodgkin's disease after 15 years. N Engl J Med 1988;318:76-81.

22. Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 1988;41:525-530.

23. Fraser MC, Tucker MA. Late effects of cancer therapy: chemotherapy-related malignancies. Oncol Nurs Forum 1988;15:67-77.

24. Osterlind A, Tucker MA, Hou-Jensen K, Stone BJ, Engholm G, Jensen OM. The Danish case-control study of cutaneous malignant melanoma: I. Importance of host factors. Int J Cancer 1988;42:200-206.

25. Osterlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case-control study of cutaneous malignant melanoma: II. Importance of UV light exposure. Int J Cancer 1988;42:319-325.

26. Osterlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case-control study of cutaneous malignant melanoma: III. Hormonal and reproductive factors in women. Int J Cancer 1988;42:821-824.

27. Osterlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case-control study of cutaneous malignant melanoma: IV. No association with nutritional factors, alcohol, smoking or hair dyes. Int J Cancer 1988;42:825-828.

28. Tucker MA, Bale SJ. Clinical aspects of familial cutaneous malignant melanoma. Semin Oncol 1988;15:524-528.

29. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358-5362.

30. Peterson LL, Woodward WR, Fletcher WS, Palmquist M, Tucker MA, Ilias A. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects. J Amer Acad Dermatol 1988;19:509-515.

31. Fraser MC, Tucker MA. Second malignancies following cancer therapy. Semin Oncol Nursing 1989;5:43-55.

32. Bale SJ, Dracopoli NC, Tucker MA, Clark WH Jr, Fraser MC, Stanger BZ, Green P, Donis-Keller H, Greene MH, Housman DE. Mapping the gene for hereditary cutaneous malignant melanoma/dysplastic nevus to chromosome 1p. N Engl J Med 1989;320:1367-11372.

33. Dracopoli NC, Harnett P, Bale SJ, Stanger BZ, Tucker MA, Housman DE, Kefford RF. Loss of alleles from distal chromosome 1p occurs late in melanoma tumor progression. Proc Natl Acad Sci 1989;86:4614-4618.

34. Hartge P, Tucker MA, Shields JA, Augsburger J, Hoover RN, Fraumeni JF Jr. Female hormones and eye melanoma: a case-control study. Cancer Res 1989;49:4622-4625.

35. Bale SJ, Tucker MA. Mutation rate estimate in hereditary cutaneous malignant melanoma/dysplastic nevi. Am J Med Genet 1990;35:293-294.

36. Caporaso N, Tucker MA, Hoover RN, Hayes R, Pickle LW, Issaq H, Muschik G, Gallo LG, Buivys D, Aisner S, Resau J, Trump B, Weston A, Harris CC. Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst 1990;82:1264-1272.

37. Caporaso N, Whitehouse J, Bertin P, Amos C, Papadopoulos N, Muller J, Whang-Peng J, Tucker MA, Fleishner TA, Marti GE. A 20 year clinical and laboratory study of B-chronic lymphocytic leukemia in a single kindred. Leukemia & Lymphoma 1990;3:331-342.

38. Shaw GL, Falk RT, Caporaso NE, Issaq HJ, Kase RG, Fox SD, Tucker MA. Effect of diurnal variation on debrisoquine metabolic phenotyping. J Natl Cancer Inst 1990;82:1573-1575.

39. Shaw GL, Tucker MA, Kase RG, Hoover RN. Problems ascertaining friend controls in a case-control study of lung cancer. Am J Epidemiol 1991;133:63-66.

40. Tucker MA, Morris-Jones PH, Boice JD Jr, Robison LL, Stone BJ, Stovall M, Jenkin RDT, Lubin JH, Baum ES, Siegel SE, Meadows AT, Hoover RN, Fraumeni JF Jr. Therapeutic radiation at a young age is linked to secondary thyroid cancer. Cancer Res 1991;51:2885-2888.

41. Fraser MC, Hartge P, Tucker MA. Epidemiology and risk factors Melanoma and non-melanoma skin cancers. Semin Oncol Nurs 1991;7:2-12.

42. Bale SJ, Goldstein AM, Tucker MA. Description of the National Cancer Institute melanoma families. Cytogenet Cell Genet 1992;59:159-160.

43. Goldstein AM, Bale SJ, Tucker MA. Linkage analysis of melanoma alone and chromosome 1p markers PND, D1S47, and LMYC. Cytogenet. Cell Genet 1992;59:203-205.

44. Caporaso NE, Shields PG, Landi MT, Shaw GL, Tucker MA, Hoover R, Sugimura H, Weston A, Harris CC. The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype. Environ Health Perspect 1992;98:101-105.

45. Amos CI, Shaw GL, Tucker MA, Hartge P. Age at onset for familial epithelial ovarian cancer. J Amer Med Assoc 1992;268:1896-1899.

46. Tucker MA, Crutcher WA, Hartge P, Sagebiel RW. Familial and cutaneous features of dysplastic nevi: a case-control study. J Am Acad Dermatol 1993;28:558-564.

47. Goldstein AM, Tucker MA, Crutcher WA, Hartge P, Sagebiel RW. The inheritance pattern of dysplastic naevi in families of dysplastic naevus patients. Melanoma Res 1993;3:15-22.

48. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993;85:25-31.

49. Tucker MA, Fraser MC, Goldstein AM, Elder DE, Guerry D. IV, Organic SM: The risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol 1993;100:350s-355s.

50. Goldstein AM, Dracopoli NC, Ho EC, Fraser MC, Kearns KS, Bale SJ, McBride OW, Clark WH Jr, Tucker MA. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p and evidence for genetic heterogeneity. Am J Hum Genet 1993;52:537-550.

51. Tucker MA. Solid second cancers following Hodgkin's disease. Hematol Oncol Clinics NA 1993;7:389-400.

52. Richardson GE, Tucker MA, Venzon DJ, Linnoila RI, Phelps R, Phares JC, Edison M, Ihde DC, Johnson BE. Smoking-related second primary cancers after successful treatment of small cell lung cancer: the effect of smoking cessation. Ann Int Med 1993;119:383-390.

53. Dosemeci M, Hayes RB, Vetter R, Hoover RN, Tucker M, Engin K, Unsal M, Blair A. Occupational physical activity, socioeconomic status, and risks of 15 cancer sites in Turkey. Cancer Causes Control 1993;4:313-321.

54. Hancock SL, Tucker MA, Hoppe RT. Factors affecting the late mortality from heart disease after treatment of Hodgkin's disease. J Am Med Assoc 1993;270:1949-1955.

55. Travis LB, Curtis RE, Glimelius B, Holowaty E, van Leeuwen FE, Lynch CE, Adami J, Gospodarowicz M, Wacholder S, Inskip P, Tucker MA, Fraumeni JF Jr, Boice JD Jr. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 1993;85:1932-1937.

56. Braun M, Tucker MA, Devesa S, Hoover RN. Seasonal variation in the diagnosis of malignant melanoma. Melanoma Res 1994;4:235-241.

57. Goldstein AM, Dracopoli NC, Engelstein M, Fraser MC, Clark WH Jr, Tucker MA. Linkage of cutaneous malignant melanoma/dysplastic nevi (CMM/DN) to chromosome 9p and evidence for genetic heterogenity. Am J Hum Genet 1994;54:489-496.

58. Haupt R, Fears TR, Rosso P, Colella R, Loicano G, de Terlizzi M, Mancini A, Comelli A, Indolfi P, Donfrancesco A, Operamolla P, Grazia G, Ceci A, Tucker MA. Increased risk of secondary leukemia after single-agent treatment with etoposide of Langerhans'cell histiocytosis. Pediatr Hemat Oncol 1994;11:499-507.

59. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark WC Jr, Tucker MA, Dracopoli NC. Germline p16 mutations in familial melanoma. Nature Genet 1994;8:15-21.

60. Novakovic B, Goldstein AM, Wexler LH, Tucker MA. Increased risk of neuroectodermal tumors and stomach cancer in relatives of patients with Ewing's sarcoma family of tumors. J Natl Cancer Inst 1994;86:1702-1706.

61. Goldstein AM, Fraser MC, Clark WH Jr, Tucker MA. Age at diagnosis and transmission of invasive melanoma in 23 cutaneous malignant melanoma/dysplastic nevi (CMM/DN) families. J Natl Cancer Inst 1994;86:1385-1389.

62. Kato S, Shields PG, Caporaso NE, Sugimura H, Trivers G, Tucker MA, Trump BF, Weston A, Harris CC. Analysis of cytochrome p450 2E1 genetic polymorphisms in relation to human lung cancer. Cancer Epidemiol Biomarkers Prev 1994;3:515-518.

63. Horn EP, Hartge P, Shields JA, Tucker MA. Sunlight and risk of uveal melanoma. J Natl Cancer Inst 1994;86:1476-1478.

64. Travis LB, Curtis RE, Stovall M, Holowaty EJ, van Leeuwen FE, Glimelius B, Lynch CF, Hagenbeek A, Li C-Y, Banks PM, Gospodarowicz MK, Adami J, Wacholder S, Inskip PD, Tucker MA, Boice JD Jr. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 1994;86:1450-1457.

65. Hartge P, Holly EA, Halpern A, Sagebiel R, Guerry D, Elder D, Clark W, Hanson L, Harrison C, Tarone R, Tucker MA. Recognition and classification of clinically dysplastic nevi from photographs: a study of inter-observer variation. Cancer Epidemiol Biomarkers Prev 1995;4:37-40.

66. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr. Radiation-induced thyroid cancer: a pooled analysis of seven studies. Radiat Res 1995;141:259-277.

67. Shaw GL, Falk RT, Deslauriers J, Frame JN, Nesbitt JC, Pass HI, Issaq HJ, Hoover RN, Tucker MA. Debrisoquine metabolism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1995;4:41-48.

68. Struewing JP, Lerman C, Kase RG, Giambarresi TR, Tucker MA. Anticipated uptake

and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epidemiol Biomarkers Prev 1995;4:169-173.

69. Travis LB, Curtis RE, Glimelius B, Holowaty EJ, van Leeuwen FE, Lynch CF, Hagenbeek A, Stovall M, Banks PM, Adami J, Gospodarowicz MK, Wacholder S, Inskip P, Tucker MA, Boice JD Jr. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995;87:524-530.

70. Novakovic B, Clark WH Jr, Fears TR, Fraser MC, Tucker MA. Melanocytic nevi, dysplastic nevi, and malignant melanoma in children from melanoma-prone families. J Am Acad Dermatol 1995;33:631-636.

71. Horn E, Tucker MA, Lambert G, Silverman D, Landi MT, Hartge P, Caporaso N. A study of gender-based P4501A2 variability: a possible mechanism for the male excess of bladder cancer. Cancer Epidemiol Biomarkers Prev 1995;4:529-533.

72. Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC. Mutations associated with familial melanoma impair $p16^{INK4}$ function. Nature Genet 1995;10:114-116.

73. Haupt R, Novakovic B, Fears TR, Byrne J, Robison LL, Tucker MA, Reaman GH. Can protocol specified doses of chemotherapy and radiotherapy be used as a measure of treatment actually received? A CCG/NIH study on long-term survivors of acute lymphocytic leukemia. J Clin Epidemiol 1996;49:687-690.

74. Struewing JP, Brody LC, Erdos MR, Kase RG, Giambarresi TR, Smith SA, Collins FS, Tucker MA. Detection of eight BRCA1 mutations in ten breast/ovarian families, including one family with male breast cancer. Am J Hum Genet 1995;57:1-7.

75. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH Jr, Tucker MA. Increased risk of pancreatic cancer in melanoma-prone kindreds with $p16^{INK4}$ mutations. New Engl J Med 1995;333:970-974.

76. Novakovic B, Fears TR, Wexler LH, McClure LL, Wilson DL, McCalla JL, Tucker MA. Experiences of cancer in children and adolescents. Cancer Nurs 1996;19:54-59.

77. Braun MM, Tucker MA. A role for photoproducts of vitamin D in the etiology of cutaneous melanoma? Medical Hypotheses 1997;48:351-354.

78. Clark WH Jr, Tucker MA, Goldstein AM. Parenchymal-stromal interactions in neoplasia. Theoretical considerations and observations in melanocytic neoplasia. Acta Oncol 1995;34:749-757.

79. Kelley MJ, Nakagawa K, Conrad NK, LeRiche J, Murray N, Lee J-S, Shaw EG, Tucker MA, Johnson BE. Genetic analysis of second primary lung cancers in patients surviving

small cell lung cancer. Clin Cancer Res 1996;2:1103-1107.

80. Weintraub M, Lin AY, Franklin J, Tucker MA, Magrath IT, Bhatia KG. Absence of germline p53 mutations in familial lymphoma. Oncogene 1996;12:687-691.

81. Nelen MR, Padberg GW, Peeters EAJ, Lin AY, Helm B, van den Frants RR, Coulon V, Goldstein AM, van Reen MMM, Easton DF, Eeles RA, Hodgsen S, Mulvihill JJ, Murday VA, Tucker MA, Mariman ECM, Starink TM, Ponder BAJ, Ropers HH, Kremer H, Longy M, Eng C. Localization of the gene for Cowden disease to chromosome 10q22-23. Nature Genetics 1996;13:114-116.

82. Lin AY, Kingma DW, Lennette ET, Fears TR, Whitehouse JM, Ambinder RF, Jaffe ES, Levine PH, Tucker MA. Epstein-Barr virus and familial Hodgkin's disease. Blood 1996;88:3160-3165.

83. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward M, Dracopoli NC. Germline mutations in the $p16^{INK4a}$ binding domain of CDK4 in familial melanoma. Nature Genet 1996;12:97-99.

84. Goldstein AM, Goldin LR, Dracopoli NC, Clark WH Jr, Tucker MA. Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi. Am J Hum Genet 1996;58:1050-1056.

85. Goldstein AM, Clark WH Jr, Fraser MC, Tucker MA. Apparent anticipation on familial melanoma. Melanoma Res 1996;6:441-446.

86. Haupt R, Fears TR, Heise A, Gadner H, Loiacono G, Terlizzi M, Tucker MA. Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in the Italian and the Austrian-German populations. Int J Cancer 1997;71:9-13.

87. Novakovic B, Goldstein AM, Tucker MA. Validation of family history of cancer in deceased family members. J Natl Cancer Inst 1996;88:1492-1493.

88. DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from the Beckwith-Wiedemann Syndrome Registry. J Pediatr 1998;132:398-400.

89. Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW, Guerry DIV, Clark WH Jr. Clinically recognized dysplastic nevi are a central risk factor for cutaneous melanoma. JAMA 1997;277:1439-1404.

90. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of *BRCA1* and *BRCA2* mutations among Ashkenazi Jews. New Engl J Med 1997;336:1401-1408.

91. Tucker MA, Murray N, Shaw EG, Ettinger DS, Mabry M, Huber MH, Feld R, Shepherd FA, Johnson DH, Grant SC, Aisner J, Johnson BE. Second cancers are related to smoking and treatment for small cell lung cancer. J Natl Cancer Inst 1997;89:1782-1789.

92. Liu L, Goldstein AM, Tucker MA, Brill H, Gruis NA, Hogg D, Lassam NJ. Affected members of melanoma prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbour mutations in the coding regions of either CDKN2B or p19ARF. Genes, Chromosomes, and Cancer 1997;19:52-54.

93. Novakovic B, Fears TR, Horowitz ME, Tucker MA, Wexler LH. Late effects of therapy in survivors of Ewing's sarcoma family of tumors. J Pediatr Hematol Oncol 1997;19:220-225.

94. Clark WH Jr, Hood AF, Tucker MA, Jampel RM. Atypical melanocytic nevi of the genital type with a discussion of reciprocal parenchymal-stromal interactions in the biology of neoplasia. Hum Pathol 1998;29:S1-S24.

95. Clark WH Jr, Tucker MA. Problems with lesions related to the development of malignant melanoma: common nevi, dysplastic nevi, malignant melanoma *in situ*, and radial growth phase malignant melanoma. Hum Path 1998;29:1-14.

96. Goldstein AM, Tucker MA. Screening for CDKN2A mutations in hereditary melanoma. J Natl Cancer Inst 1997;89:676-678.

97. Ping YJ, Nakatsu Y, Goldstein AM, Tucker MA, Kraemer KH, Tanaka K. RPA2, a gene for the 32kDa subunit of replication protein A on chromosome 1p35-36, is not mutated in patients with familial melanoma linked to chromosome 1p36. Melanoma Res 1998;8:47-52.

98. Lin AY, Nutman TB, Kaslow D, Mulvihill JJ, Fontaine L, White BJ, Knutsen T, Theil KS, Raghuprasad PK, Goldstein AM, Tucker MA. Familial eosinophilia: clinical and laboratory results on a US kindred. Am J Med Genet 1998;76:229-237.

99. Fraser MC, Goldstein AM, Tucker MA. The genetics of melanoma. Semin. Oncol Nurs 1997;13:108-114.

100. Goldstein AM, Yuen J, Tucker MA. Second cancers after medulloblastoma: population-based results from the United States and Sweden. Cancer Causes Ctl 1997;8:865-871.

101. Wacholder S, Hartge P, Struewing JP, Pee D, Brody L, Tucker M. The kin-cohort study for estimating penetrance. Am J Epidemiol 1998;148:623-30.

102. Moriwaki S-I, Tarone RE, Tucker MA, Goldstein AM, Kraemer KH. Hypermutability of UV-treated plasmids in dysplastic nevus/familial melanoma cell lines. Cancer Res 1997;57:4637-4641.

103. Pollock PM, Spurr N, Bishop T, Newton-Bishop J, Gruis N, Goldstein AM, Tucker MA,

Foulkes W, Barnhill R, Haber D, Fountain J, Hayward NK. Haplotype analysis of two recurrent *CDKN2A* mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mutat 1998;11:424-431.

104. Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, McLaughlin J, Hogg D, Lassam NJ. *CDKN2A* mutations in multiple primary melanomas. New Engl J Med 1998;338:879-887.

105. Goldstein AM, Falk RT, Fraser MC, Dracopoli NC, Sikorski RS, Clark WH Jr, Tucker MA. Sun-related risk factors in melanoma-prone families with *CDKN2A* mutations. J Natl Cancer Inst 1998;90:709-711.

106. Shaw GL, Falk RT, Frame JN, Weiffenbach B, Nesbitt JC, Pass HI, Caporaso NE, Moir DT, Tucker MA. Genetic polymorphism of CYP2D6 and lung cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:215-220.

107. Woodage T, King SM, Wacholder S, Hartge P, Struewing JP, McAdams M, Laken SJ, Tucker MA, Brody LC. A community-based study of the APC I1307K allele in Ashkenazi Jews: association with increased risk of cancers including colorectal and breast cancer. Nature Genet 1998;20:62-65.

108. Rioux JD, Stone VA, Daly MJ, Cargill M, Green T, Nguyen H, Nutman T, Zimmerman PA, Tucker MA, Hudson T, Goldstein AM, Lander E, Lin AY. Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33. Am J Hum Genet 1998;63:1086-1094.

109. Lee JS, Struewing JP, Wacholder S, McAdams M, Pee D, Brody LC, Tucker MA, Hartge P. Survival after breast cancer in Ashkenazi Jewish BRCA1/2 mutation carriers. J Nat'l Cancer Inst 1999;91:259-263.

110. Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. The prevalence of common *BRCA1* and *BRCA2* mutations among Ashkenazi Jews. Am J Hum Genet 1999;64:963-970.

111. Kefford R, Newton Bishop J, Bergman W, Tucker M. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999;17:3245-3251.

112. Landi MT, Calista D, Landi G, Bernucci I, Bertazzi PA, Clark WH Jr, Goldstein AM, Tucker MA. Clinical characteristics of twenty Italian melanoma-prone families. Arch Dermatol 1999;135:1554-1555.

113. Newton Bishop JA, Harland M, Bennett DC, Bataille V, Goldstein AM, Tucker MA, Ponder BAJ, Cuzick J, Selby P, Bishop DT. Mutation testing in melanoma families: *INK4A, CDK4,* and *INK4D*. Br J Cancer 1999;80:295-300.

114. Harty LC, Garcia-Closas M, Rothman N, Reid YA, Tucker MA, Hartge P. Collection of

buccal cell DNA using treated cards. Cancer Epidemiol Biomarkers Prev 2000;9:501-506.

115. Cope JU, Tsokos M, Helman LJ, Gridley G, Tucker MA. Inguinal hernia in patients with Ewing sarcoma: a clue to etiology. Med Ped Oncol 2000;34:195-199.

116. Harland M, Holland EA, Ghiorzo P, Mantelli M, Bianchi-Scarra G, Goldstein AM, Tucker MA, Ponder BAJ, Mann GJ, Bishop DT, Bishop JN. Mutation screening of the CDKN2A promoter in melanoma families. Genes, Chromosomes & Cancer 2000;28:45-57.

117. Shennan MG, Badin AC, Walsh S, Summers A, From L, McKenzie M, Goldstein AM, Tucker MA, Hogg D, Lassam N. Lack of germline CDK6 mutations in familial melanoma. Oncogene 2000;19:1849-1852.

118. Tucker M, Goldstein A, Dean M, Knudson A. NCI workshop report: the phakomatoses revisited. J Natl Cancer Inst 2000;92:530-533.

119. Wang W, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, Suthers G, Tucker MA, Kaufman DJ, Doody MM, Tarone RE, Daly M, Levavi H, Pierce H, Chetrit A, kConFab, ABCFS/CFRBCS, AJBCS, NISOC, Yechezkel GH, Chenevix-Trench G, Offit K, Godwin AK, Struewing JP. A single nucleotide polymorphism in the 5'untranslated region of *RAD51* and risk of cancer among *BRCA1/2* mutation carriers. Cancer Epidemiol Biomarkers Prev 2001; 10:955-960.

120. Goldstein AM, Martinez M, Tucker MA, Demenais F. Gene-covariate interaction between dysplastic nevi and the *CDKN2A* gene in American melanoma-prone families. Cancer Epidemiol Biomarkers Prev 2000;9:889-894.

121. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in American melanoma-prone families with *CDKN2A* and *CDK4* mutations. J Natl Cancer Inst 2000;92:1006-1010.

122. Kleinerman RA, Tarone RE, Abramson DH, Seddon JM, Li FP, Tucker MA. Hereditary retinoblastoma and risk of lung of cancer. J Natl Cancer Inst 2000;92:2037-2039.

123. Olsen JH, Hanemann JM, Borresen-Dale AL, Brondum-Nielsen K, Hammarstrom L, Kleinerman R,Kaariainen H, Lonnqvist T, Sankila R, Seersholm N, Tretli S, Yuen J, Boice JD Jr., Tucker M. Cancer in patients with Ataxia-Telangiectasia and in their relatives in the nordic countries. J Natl Cancer Inst 2001;93:121-127.

124. Ciotti P, Struewing JP, Mantelli M, Chompret A, Avril MF, Santi PL, Tucker MA, Scarra-Bianchi G, Paillerets BB, and Goldstein AM. A Single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. Am J Hum Genet 2000;67:311-319.

125. Jemal A, Devesa SS, Hartge P, Tucker MA. Cancer Surveillance Series: Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst 2001;93:678-683.

126. Laake K, Jansen L, Hahnemann JM, Brondum-Nielsen K, Lonnqvist T, Kaariainen H, Sankila R, Lahdesmaki A, Hammarstrom L, Yuen J, Tretli S, Heiberg A, Olsen JH, Tucker M, Kleinerman R, Borresen-Dale AL. Characterization of *ATM* mutations in 41 Nordic families with ataxia telangiectasia. Hum Mutat 2000;16:232-246.

127. Hartge P, Chatterjee N, Wacholder S, Brody LC, Tucker MA, Struewing JP. Breast cancer risk in Ashkenazi *BRCA1/2* mutation carriers: Effects of reproductive history. Epidemiol 2002;13:255-61.

128. Modan B, Hartge P, Hirsch-Yechezkel G, Ghetrit A, Lubin F, Beller U, Ben-Baurch G, Fishman A, Menczer J, Struewing JP, Tucker MA, Wacholder S. Oral contraceptives, parity and *BRCA* mutations in the etiology of ovarian cancer in Israeli Jews. New Engl J Med 2001;345:235-240.

129. Chatterjee N, Wacholder S, Shih J, Hartge P, Brody L, Tucker M, Struewing J. Association and aggregation analysis using kin-cohort designs with applications to genotype and family history data from the Washington Ashkenazi Study. Genet Epidemiol 2001; 21:123-138.

130. Landi MT, Baccarelli A, Calista D, Fears T, Tucker MA, Landi G. Combined risk factors for melanoma in a Mediterranean population. Br J Cancer 2001;85:1304-1310.

131. Goldstein AM, Tucker MA. Genetic epidemiology of cutaneous melanoma - A global perspective. Arch Dermatol 2001;137:1493-1496.

132. Goldstein AM, Liu L, Shennan MG, Hogg D, Tucker MA, Struewing JP. A common founder for the V126D *CDKN2A* mutation in seven North American melanoma-prone families. Br J Cancer 2001;85:527-530.

133. Tucker MA, Fraser MC, Goldstein AM, Struewing JP, King MA, Crawford JT, Chiazze EA, Zametkin DP, Fontaine LS, Clark WH, Jr. A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families. Cancer 2002;94:3192-3209.

134. Harty LC, Lin AY, Goldstein AM, Jaffe ES, Carrington M, Tucker MA, Modi WS. HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. Blood 2002;99:690-693.

135. Fears TR, Bird CC, Guerry D IV, Sagebiel RW, Gail MH, Elder DE, Halpern A, Holly EA, Hartge P, Tucker MA. Average midrange ultraviolet radiation flux and time outdoors predict melanoma risk. Cancer Res 2002;62:3992-3996.

136. Landi MT, Baccarelli A, Tarone RE, Pesatori A, Tucker MA, Hedayati M, Grossman L.

DNA repair, dysplastic nevi and sunlight sensitivity in the development of cutaneous malignant melanoma. J Natl Cancer Inst 2002;94:94-101.

137. Goldstein AM, Chidambaram A, Halpern A, Holly EA, Guerry IV D, Sagebiel R, Elder DE, Tucker MA. Rarity of CDK4 germline mutations in familial melanoma. Melanoma Res 2002;12:51-55.

138. Bishop DT, Demenais FM, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis NA, Hansson J, Harland M, Hayward NK, Holland EA, Mann G, Mantelli M, Nancarrow D, Platz A, Tucker MA. Geographic variation in the penetrance of *CDKN2A* mutations for melanoma. J Natl Cancer Inst 2002;94:894-903.

139. Feng Y, Shi J, Goldstein AM, Tucker MA, Nelson MA. Analysis of mutations and identification of several polymorphisms in the putative promoter region of the $p34^{cdc2}$-related *CDC2L1* gene located at 1p36 in melanoma cell lines and melanoma families. Int J Cancer 2002;99:834-838.

140. Kefford R, Newton-Bishop J, Tucker M, Bressac-de Paillerets B, Bianchi-Scarra G, Bergman W, Goldstein A, Puig S, MacKie R, Elder D, Hansson J, Hayward N, Hogg D, Olsson H for the Melanoma Genetics Consortium. Genetic testing for melanoma. Lancet Oncology 2002;3:653-654.

141. Gillanders D, Hank Juo SH, Holland EA, Jones M, Nancarrow D, Freas-Lutz D, Sood R, Park N, Faruque M, Markey C, Kefford RF, Palmer J, Bergman W, Bishop DT, Tucker MA, Bressac-de Paillerets B, Hansson J, Stark M, Gruis N, Bishop JN, Goldstein AM, Bailey-Wilson JE, Mann GJ, Hayward N, Trent J, Lund Melanoma Study Group; Melanoma Genetics Consortium. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 2003;73:301-313.

142. Rutter JL, Wacholder SW, Chetrit A, Lubin F, Menczer J, Ebbers SM, Tucker MA, Struewing JP, Hartge P. Gynecologic surgeries and risk of ovarian cancer in carriers and non-carriers of the *BRCA1* and *BRCA2* Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst 2003;95:1072-1078.

143. Rutter JL, Goldstein AM, Davila MR, Tucker MA, Struewing JP. *CDKN2A* point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both $p16^{INK4}$ and $p14^{ARF}$. Oncogene 2003;22:4444-4448.

144. Rutter JL, Smith AM, Davila MR, Sigurdson AJ, Giusti RM, Pineda MA, Doody MM, Tucker MA, Greene MH, Zhang J, Struewing JP. Mutational analysis of the *BRCA1*-interacting genes *ZNF350/ZBRK1* and *BRIP1/BACH1* among *BRCA1* and *BRCA2*-negative probands from breast- ovarian cancer families and among early onset breast cancer cases and reference individuals. Human Mutat 2003;22:121-128.

145. Loo JC, Liu L, Hao A, Gao L, Agatep R, Shennan M, Summers A, Goldstein AM, Tucker MA, Deters C, Fusaro R, Blazer K, Weitzel J, Lassam N, Lynch H, Hogg D.

Germline splicing mutations of *CDKN2A* predispose to melanoma. Oncogene 2003;22:6387-6394.

146. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003;21:2397-2406.

147. Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene 2003;22:3042-3052.

148. Rutter JL, Bromley CM, Goldstein AM, Elder DE, Holly EA, Guerry D IV, Hartge P, Struewing JP, Hogg, D, Halpern A, Sagebiel RW, Tucker MA. Heterogeneity of risk for melanoma pancreatic cancer and digestive cancers: a melanoma case-control study. Cancer 2004; 101:2809-2816.

149. Fraser MC, Goldstein AM, Tucker MA. Genetic testing for inherited predisposition to melanoma: Has the time come? The Melanoma Letter (a publication of The Skin Cancer Foundation). The Melanoma Letter 2003;21:3-4; also J Drugs Dermatol 2004;3:93-5.

150. Millen AE, Tucker MA, Hartge P, Halpern A, Elder DE, Guerry D IV, Holly EA, Sagebiel RW, Potishman N. Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev 2004; 13:1042-51.

151. Goldstein AM, Struewing JP, Fraser MC, Smith MW, Tucker MA. Prospective risk of cancer in CDKN2A germline mutation carriers. J Med Genet 2004;41:421-424.

152. Struewing JP, Hartge P, Wacholder S, Tucker MA, Greene MH. BRCA1 and sex ratio. Eur J Hum Genet 2004;12:663-667.

153. Wacholder S, Struewing JP, Hartge P, Greene MH, Tucker MA. Breast cancer risks for BRCA1/2 carriers. Science 2004;306:2187-2191.

154. Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M, Li FP, Fraumeni JF Jr. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 2005; 23:2272-2279.

155. Goldin LR, McMaster ML, Ter-Minassian M, Saddlemire S, Harmsen B, Lalonde G, Tucker MA. A genome screen of families at high risk for Hodgkin lymphoma: Evidence for a susceptibility gene on chromosome 4. J Med Genet 2005; 42:595-601.

156. Harland M, Taylor CF, Chambers PA, Kukalizch K, Randerson-Moor J, Gruis NA, deSnoo FA, Ter Huurne JAC, Goldstein AM, Tucker MA, Bishop DT, Newton Bishop JA. A mutation hotspot at the p14ARF splice site. Oncogene 2005;24:4604-4608.

157. Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric melanoma: Risk factor and survival analysis of the Surveillance, Epidemiology, and End Results database. J Clin Oncol 2005;23:4735-4741.

158. Goldstein AM, Landi MT, Tsang S, Fraser MC, Munroe D, Tucker MA. Association of *MC1R* variants and risk of melanoma in melanoma-prone families with *CDKN2A* mutations. Cancer Epidemiol Biomarkers Prev 2005;14:2208-12.

159. Laud K, Marian C, Avril M-F, Barrois M, Chompret A, Goldstein AM, Tucker MA, Clark PA, Peters G, Chaudru V, Demenais F, Spatz A, Smith MW, Lenoir GM, Bressac-de Paillerets B. Comprehensive analysis of cdkn2a (p16ink4a/p14arf) and cdkn2b genes in 53 melanoma index cases considered to be at heightened risk of melanoma. J Med Genet 2006; 43:39-47.

160. Olsen JH, Hahnemann JMD, Borresen-Dale A-L, Tretli S, Kleinerman R, Sankila R, Hammarstrom L, Robsahm TE, Kaariainen H, Bregard A, Brondum-Neilsen K, Yuen J, Tucker MA. Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia. Br J Cancer 2005; 93:260-265.

161. McMaster ML, Giambarresi T, Vasquez L, Goldstein AM, Tucker MA. Cytogenetics of familial Waldenstrom=s macroglobulinemia: in pursuit of an understanding of genetic predisposition. Clin Lymphoma 2005; 5:230-234.

162. Kleinerman RA, Stovall M, Tarone RE, Tucker MA. Gene environment interactions in a cohort of irradiated retinoblastoma patients. Radiat Res 2005; 165:701-702.

163. Travis L, Rabkin C, Morris Brown L, Allan J, Alter B, Ambrosone C, Begg C, Caporaso N, Chanock S, DeMichele A, Figg W, Gospodarowicz M, Hall E, Hisada M, inskip P, Kleinerman R, Little J, Malkin D, Ng A, Offit K, Pui C-H, Robison L, Rothman N, Shields P, Strong L, Taniguchi T, Tucker M, Greene M. Cancer survivorship- genetic susceptibility and second primary cancer: Research strategies and recommendations. J Natl Cancer Inst 2006;98:15-25.

164. Buckel TB, Goldstein AM, Fraser MC, Rogers B, Tucker MA. Recent tanning bed use: a risk factor for melanoma. Arch Dermatol 2006;142:485-488.

165. Fears TR, Guerry D IV, Pfeiffer RM, Sagebiel RW, Elder DE, Halpern AC, Holly EA, Hartge P, Tucker MA. Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol 2006;24:3590-6.

166. Kleinerman RA, Tucker MA, Abramson DH, Seddon JM, Tarone RE, Fraumeni JF Jr. Risk by individual subtypes of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 2007;99:24-31.

167. McMaster ML, Goldin LR, Bai Y, Ter-Minassian M, Boehringer S, Giambarresi TR, Vasquez LG, Tucker MA. Genome-wide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families. Am J Hum Genet 2006;79:695-701.

168. Foster MC, Kleinerman RA, Abramson DH, Seddon JM, Tarone RE, Tucker MA. Tobacco use in adult long-term survivors of retinoblastoma. Cancer Epidemiol

Biomarkers Prev 2006;15:1464-8.

169. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril M-F, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon-Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, MacKie RM, Magnusson V, Mann GJ, Niendorf K, Newton Bishop J, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E, the Lund Melanoma Study Group, and the Melanoma Genetics Consortium (GenoMEL). High-risk melanoma susceptibility genes and their association with pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006; 66:9818-28.

170. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Cannon-Albright LA, Chaudru V, Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman S, MacKie RM, Magnusson V, Mann G, Newton-Bishop J, Palmer JM, Puig S, Puig-Butille JA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E, the Lund Melanoma Study Group, the Melanoma Genetics Consortium (GenoMEL). Features associated with germline CDKN2A mutations: A GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007;44:99-106.

171. Lea S, Holly EA, Hartge P, Lee JS, Guerry D IV, Elder DE, Halpern A, Sagebiel RW, Tucker MA. Reproductive risk factors for cutaneous melanoma in women: a case-control study. Am J Epidemiol 2007; 165:505-13.

172. Goldstein AM, Chaudru V, Ghiorzo P, Badenas C, Malvehy J, Pastorino L, Laud K, Hulley B, Avril MF, Puig-Butille JA, Miniere A, Marti R, Chompret A, Cuellar F, Kolm I, Mila M, Tucker MA, Demenais F, Bianchi-Scarra G, Puig S, de Paillerets BB. Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries. Int J Cancer 2007;121:825-31.

173. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willet WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39:645-9.

174. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover RN, Thomas G, Chanock SJ. A genome-wide association study identifies alleles in *FGFR2* associated

with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870-4.

175. Levy RM, Ming ME, Shapiro M, Tucker M, Guerry D IV, Cirillo-Hyland VA, Elenitsas R. Eruptive disseminated Spitz nevi. J am Acad Dermatol 2007; 57:519-23.

176. NCI-NHGRI Working Group on Replication in Association Studies, Chanock SJ, ManolioT, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, Hirschhorn JN, Abecasis G, Altshuler D, Bailey-Wilson JE, Brooks LD, Cardon LR, Daly M, Donnelly P, Fraumeni JF Jr, Freiner NB, Gerhard DS, Gunter C, Guttmacher AE, Guyer MS, Harris EL, Hoh J, Hoover R, Kong CA, Merikangas KR, Morton CC, Palmer LJ, Phimister EG, Rice JP, Roberts J, Rotimi C, Tucker MA, Vogan KJ, Wacholder S Wijsman EM, Winn DM, Collins FS. Replicating genotype-phenotype associations. Nature 2007; 447:655-60.

177. McMaster ML, Csako G, Giamberrasi TR, Vasquez L, Merg M, Saddlemire S, Hulley B, Tucker MA. Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families. Clin Cancer Res 2007;13:5063-9.

178. Gerstenblith MR, Goldstein AM, Tucker MA, Fraser MC. Genetic testing for melanoma predisposition: current challenges. Cancer Nurs 2007;30:452-9

179. Stewart L, Glenn GM, Stratton P, Goldstein AM, Merino MJ, Tucker MA, Linehan WM, Toro JR. Germline mutations in the fumarate hydratase gene confer a predisposition to uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer. Arch Dermatol 2008;144:1584-92.

180. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Berndt S, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannuci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hayes RB, Hunter DJ, Chanock SJ. Multiple novel loci identified in a genome-wide association study of prostate cancer. Nature Genet 2008;40:310-5.

181. Goldstein AM, Stacey SN, Olafsson JH, Jonsson GF, Helgason A, Suslem P, Sigurgeirsson B, Benediktsdottir KR, Thorisdottir K, Ragnarsson R, Kjartansson J, Kostic J, Masson G, Kristjansson K, Gulcher JR, Kong A, Thorsteindottir U, Rafnar T, Tucker MA, Stefansson K. *CDKN2A* mutations and melanoma risk in the Icelandic population. J Med Genet 2008;45:284-9.

182. Purdue MP, Beane-Freeman L, Anderson WWF, Tucker MA. Recent trends in incidence of cutaneous melanoma among U.S. Caucasian young adults. J Invest Dermatol 2008;128:2905-8.

183. Harland M, Goldstein AM, Kukalizch K, Taylor C, Hogg D, Puig S, Badenas C, Gruis N, ter Huurne J, Bergman W, Hayward NK, Start M, Tsao H, Tucker MA, Landi MT, Bianchi Scarra G, Ghiorzo P, Kanetsky PA, Elder D, Mann GJ, Holland EA, Bishop

DT, Bishop JN. A comparison of *CDKN2A* mutation detection within the Melanoma Genetics Consortium (GenoMEL). Eur J Cancer 2008;44:1269-74.

184. Sheen V, Tucker MA, Abramson DH, Seddon JM, Kleinerman RA. Cancer screening practices of adult survivors of retinoblastoma at risk of second cancers. Cancer 2008;113:434-41.

185. Sulem P, Gudbjartsson DF, Stacey SN, Helgason A, Rafnar T, Jakobsdottir M, Steinberg S, Gudjonsson SA, Palsson A, Thorleifsson G, Palsson S, Sigurgeirsson B, Thorisdottir K, Ragnarsson R, Benediktsdottir KR, Aben KK, Vermeulen SH, Goldstein AM, Tucker MA, Kiemeney LA, Olafsson JH, Gulcher J, Kong A, Thorsteinsdottir U, Stefansson K. Two newly identified genetic determinants of pigmentation in Europeans. Nat Genet 2008;40:835-7.

186. Gudbjartsson DF, Sulem P, Stacey SN, Goldstein AM, Rafnar T, Sigurgeirsson B, Benediktsdottir KR, Thorisdottir K, Ragnarsson R, Sveinsdottir SG, Magnusson V, Linblom A, Kostulas K, Botella-Estrada R, Soriano V, Juberias P, Grasa M, Saez, B, Andres R, Scherer D, Rudnai P, Gurzau E, Koppova K, Kiemeney LA, Jakobsdottir M, Steinberg S, Helgason A, Gretarsdottir S, Tucker MA, Mayordomo JI, Nagore E, Kumar R, Hansson J, Olafsson JH, Gulcher J, Kong A, Thorsteinsdottir U, Stefansson K. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 2008;40:886-91.

187. Landi MT, Consonni D, Rotunno M, Bergen AW, Goldstein AM, Lubin JH, Goldin L, Alavanja M, Morgan G, Subar AF, Linnoila I, Previdi F, Corno M, Rubagotti M, Marinelli B, Albetti B, Colombi A, Tucker M, Wacholder S, Pesatori AC, Caporaso NE, Bertazzi PA. Environment And Genetics in Lung cancer Etiology (EAGLE) study: an integrative population-based case-control study of lung cancer. BMC Public Health 2008;8:203.

188. Ng D, Yang XR, Tucker MA, Goldstein AM. Mutation screening of *CHD5* in melanoma-prone families linked to 1p36 revealed no deleterious coding or splice site changes. BMC Res Notes 2008;1:86.

189. Yu C-L, Tucker MA, Abramson DH, Seddon JM, Stovall M, Fraumeni, JF Jr, Kleinerman RA. Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst (in press).

Publications (non peer reviewed)

1. Tucker MA, Fraumeni JF Jr. Soft Tissue. In: D Schottenfeld, JF Jr Fraumeni (eds). Cancer Epidemiol Prev. Philadelphia, WB Saunders 1982;827-836.

2. Tucker MA, Meadows AT, Boice JD, Hoover RN, Fraumeni JF Jr. Cancer risk following treatment of childhood cancer. In: JD Jr Boice, JF Jr Fraumeni (eds).

Radiation Carcinogenesis: Epidemiology and Biological Significance. New York, Raven Press 1984;211-224.

3. Tucker MA, Fraumeni JF Jr. Soft Tissue. In: D Schottenfeld, JF Jr Fraumeni (eds). Cancer Epidemiol Prev. Philadelphia, WB Saunders 1982;827-836.

4. Tucker MA, Boice JD, Hoffman DA. Second cancer following cutaneous melanoma, and cancers of the brain, thyroid, connective tissue, bone and eye in Connecticut, 1935-82. Monogr Natl Cancer Inst 1985;68:161-189.

5. Tucker MA, Hartge P, Shields JA. Epidemiology of intraocular melanoma. In: RP Gallagher (ed). Recent Results in Cancer Research. Vol 102, Epidemiology of Malignant Melanoma. Philadelphia, Springer-Verlag 1985;156-165.

6. Greene MH, Elder DE, Tucker MA, Guerry D. The dysplastic nevus syndrome. In: U Veronese, N Cascinelli, M Santinami (eds). Cutaneous Malignant Melanoma in 1985. London, Academic Press 1987;279-318.

7. Tucker MA. Individuals at high risk of melanoma. In: M Elwood, RM MacKie (eds). Pigment Cell. Vol 9, Melanoma and Naevi: Incidence, Interrelationships, and Implications. 1988;95-109.

8. Tucker MA. Where dysplastic nevi have led us. In: Miller RW, et al (eds). Unusual Occurrences as Clues to Cancer Etiology. Japan Sci Soc Press, Tokyo/Taylor & Francis, Ltd, 1988;251-259.

9. Coleman CN, Tucker MA. Secondary Cancers. In: VT Jr DeVita, S Hellman, SA Rosenberg (eds). Cancer: Principles and Practice of Oncology. 3rd Edition. Philadelphia: JB Lippincott Co 1989;2181-2190.

10. Tucker MA. Familial Hodgkin disease. In: ML Buyse (ed). Birth Defects Encyclopedia. Dover MA, Blackwell Scientific Publications 1990;266.

11. Tucker MA. Familial cutaneous melanoma. In: ML Buyse (ed). Birth Defects Encyclopedia. Dover MA, Blackwell Scientific Publications 1990;267-268.

12. Idhe DC, Tucker MA. Second primary malignancies in small cell lung cancer: a major consequence of modest success. J Clin Oncol 1992;10:1511-1513.

13. Bale SJ, Dracopoli NC, Tucker MA. The genetics of human cutaneous malignant melanoma. In: CM Balch, AN Houghton, AJ Sober, GW Milton, SJ Soong (eds). Cutaneous Melanoma, Second Edition. Philadelphia: JB Lippincott Co 1992;93-100.

14. Tucker MA, Caggana M, Kelsey KT, Coleman CN. Secondary cancers. In: JF Holland, E Frei, RC Bast, DW Kufe, DL Morton, RR Weichselbaum (eds). Cancer Medicine, Third Edition. Philadelphia: Lea & Febiger 1993;2402-2415.

15. Tucker MA. Secondary cancers. In: VT Jr DeVita, S Hellman, SA Rosenberg (eds). Cancer: Principles and Practice of Oncology, Fourth Edition. Philadelphia, PA Lippincott Co 1993;2407-2416.

16. Goldstein AM, Tucker MA. Etiology, epidemiology, risk factors, and public health issues of melanoma. Current Opinion in Oncology 1993;5:358-363.

17. Tucker MA. Skin care guidelines for melanoma-prone families. The 1993 Skin Cancer Foundation Journal 1993;76-77.

18. Goldstein AM, Tucker MA. Familial melanoma and its management. In: R Eeles, B Ponder, D Easton, A Horwich (eds). Genetic Predisposition to Cancer. London: Chapman and Hall 1996;333-343.

19. Clark WH Jr, Goldstein AM, Tucker MA. Prospectives for cutaneous malignant melanoma: Considerations of the precursor state and heritability. In: R Mackie (ed). Melanoma: Cutaneous and Ocular. Brit Med Bull 1995;51:717-746.

20. Zahm SH, Tucker MA, Fraumeni JF Jr. Soft Tissue. In: D Schottenfeld, JF Jr Fraumeni, (eds). Cancer Epidemiology and Prevention, Second Edition. Philadephia: WB Saunders Company 1996;984-999.

21. Struewing JP, Watson P, Easton DF, Ponder BAJ, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. Monograph Natl Cancer Inst 1995;17:33-36.

22. Goldstein AM, Tucker MA. Genetic epidemiology of familial melanoma. Dermatol Clinics 1995;13:605-612.

23. Levine PH, Lin AY, Tucker MA. What can we learn about the aetiology of Hodgkin's disease from family studies? In: R Jarrett (ed). The Aetiology of Hodgkin's Disease, New York: Plenum Press 1995;27-32.

24. Lin AY, Tucker MA. Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma. In: GP Canellos, TA Lister, JL Sklar (eds). The Lymphomas, Philadelphia: WB Saunders Company 1997;43-61.

25. van Leeuwen FE, Swerdlow AJ, Valagussa P, Tucker MA. Second cancer after treatment of Hodgkin=s Disease. In: PM Mauch, JO Armitage, et al (eds). Hodgkin's Disease 1999;33:607-632.

26. Tucker MA. Nevi, sun exposure and the risk of melanoma. In: SA Jr Wells, PA Sharp (eds). Accomplishments in Cancer Research 1997, General Motors Cancer Research Foundation: Lippincott Williams and Wilkins 1998;162-172.

27. Hancock SL, Tucker MA. Second Cancers: Can we affect risk? ASCO Educational Booklet 1998;74-79.

28. Tucker M. Major cancer susceptibility genes and radiation: What do we know? Radiat Res 2000;154:740-741.

29. Tucker, MA. Epidemiologic Methods. In: VT DeVita, S Hellman, SA Rosenberg (eds). Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins pp. 219-227, 2001.

30. Goldstein AM, Tucker MA. Familial melanoma and its management. In: RA Eeles, DF Easton, BAJ Ponder, C Eng (eds.) Genetic Predisposition to Cancer, 2nd Edition. London:Arnold, a member of the Hodder Headline Group, pp 352-359, 2004.

31. Fears TR, Tucker MA. Re: Sun exposure and mortality from melanoma. J Natl Cancer Inst 2005;97:1789-1790.

32. Goldstein AM, Tucker MA. A piece of the melanoma puzzle. J Natl Cancer Inst 2005; 97:1486-1487.

33. Tucker MA. Does radiotherapy dose correlate with incidence of thyroid cancer in survivors of childhood tumours? Nature Clin Practice Endocrinology and Metabolism 2006;2:68-69.

34. Ishibe N, Tucker MA. Epidemiology of Hodgkin=s and Non-Hodgkin=s Lymphomas. In: Canellos G, Lister A, Sklar M (eds.) The Lymphomas 2nd Ed. Williams Lippincott, Boston pp 127-138, 2006.

35. Tucker MA. Sun exposure measurements in populations. Nutr Rev 2007; 65:S84-6.

36. Lee JS, Tucker MA. Making sense of puzzling genetic association studies: a team approach. Ann Int Med 2006;145:302-304.

37. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. (eds). New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute, NIH Publication No. 05-5302. Bethesda, MD, 2006.

38. Fraumeni JF, Fr, Curtis RE, Edwards BK, Tucker MA. Introduction. In: Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. (eds). New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute, NIH Publication No. 05-5302. Bethesda, MD, 2006. pp1-9.

39. Caporaso NE, Dodd KW, Tucker MA. New malignancies following cancer of the respiratory tract. In: Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. (eds). New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute, NIH Publication No. 05-5302. Bethesda, MD, 2006. pp145-180.

40. McMaster ML, Feuer EJ, Tucker MA. New malignancies following cancer of the male genital tract. In: Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. (eds). New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute, NIH Publication No. 05-5302. Bethesda, MD, 2006. pp257-284.

41. Freedman DM, Miller BA, Tucker MA. New malignancies following melanoma of the skin, eye melanoma, and non-melanoma eye cancer. In: Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. (eds). New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute, NIH Publication No. 05-5302. Bethesda, MD, 2006. pp339-362.

42. Tucker MA. Atypical melanocytic nevi (Chapter 123). In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ (eds). Fitzpatrick's Dermatology in General Medicine, Seventh Edition. McGraw-Hill Companies. New York, NY, 2007.

43. Tucker MA. Is sunlight important to melanoma causation? Cancer Epidemiol Biomarkers Prev 2008;17:467-8.